Drug/Small Molecule:
atenolol

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with atenolol that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105073

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all atenolol variant annotations

Gene ? Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA ADRB1 H1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1008899 -242+29754G>A, -320+29754G>A, -360G>A, 122+29754G>A, 156238G>A, 3653711G>A, 55862847G>A, 98+29754G>A
G > A
Intronic
No VIP available CA VA
rs10157410 154193G>C, 186947224G>C, 1960+304G>C, 38435866G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs1024323 1527397C>T, 3006043C>T, 329C>T, 425C>T, 45701C>T, Ala110Val, Ala142Val
C > T
Missense
Ala142Val
No VIP available CA VA
rs10267099 -330-48366C>T, 123-1378G>A, 25311603G>A, 68805C>T, 87278760G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs1042711 -47C>T, 148206348C>T, 5193C>T, 9369275C>T, ADRB2: Arg-19Cys, T-47C
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs1042713 148206440G>A, 148206440G>G, 46A>A, 46A>G, 46G>A, 5285A>A, 5285A>G, 9369367G>A, 9369367G>G, ADRB2:16Arg>Gly, ADRB2:Arg16Gly, ADRB2:Gly16Arg, Arg16, Arg16=
G > A
Missense
Arg16Gly
No VIP available No Clinical Annotations available VA
rs1042714 148206473G>C, 148206473G>G, 318C>G, 5318C>G, 79C>G, 9369400G>C, 9369400G>G, ADRB2:27Glu>Gln, ADRB2:79C>G, ADRB2:Gln27Glu, Gln27
G > C
Missense
Gln27Glu
No VIP available CA No Variant Annotations available
rs1051375 2728879G>A, 2788879G>A, 334-1816C>T, 5328G>A, 5352G>A, 5361G>A, 5379G>A, 5385G>A, 5412G>A, 5418G>A, 5421G>A, 5445G>A, 5484G>A, 5505G>A, 713928G>A, Thr1776=, Thr1784=, Thr1787=, Thr1793=, Thr1795=, Thr1804=, Thr1806=, Thr1807=, Thr1815=, Thr1828=, Thr1835=
G > A
Synonymous
Thr1806Thr
No VIP available CA VA
rs11039149 -92-4667A>G, 11825A>G, 47216675A>G, 47276675A>G, 62-4667A>G
A > G
Intronic
No VIP available CA VA
rs11064426 45677A>C, 45677A>T, 6893257A>C, 6893257A>T, 6953257A>C, 6953257A>T, 699+115A>C, 699+115A>T, 8883A>C, 8883A>T
A > T
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs1137617 11243821A>G, 150648198A>G, 1956 C>T, 1956T>C, 31817T>C, 936T>C, Tyr312=, Tyr652=
A > C
A > G
Stop Codon
Tyr312null
Tyr312Tyr
No VIP available No Clinical Annotations available VA
rs11603334 -317C>T, 17738780G>A, 509+4680C>T, 72432985G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs12069113 *1487+172C>T, 113214413C>T, 83186331C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs12076902 113167536G>A, 39+5031G>A, 83139454G>A
G > A
Intronic
No VIP available CA VA
rs12595985 143877C>A, 53876751C>A, 7490950C>A, 752-1316C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs1458038 5712444C>T, 81164723C>T
C > T
Not Available
rs1799752 16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 26840042_26840043insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, ACE D/I
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
Intronic
No VIP available No Clinical Annotations available VA
rs1799945 118C>G, 187C>G, 26031179C>G, 26091179C>G, 77-1734C>G, 77-2168C>G, 77-363C>G, 8671C>G, HFE: H63D, HFE: His63Asp, His40Asp, His63Asp
C > G
Intronic
His40Asp
No VIP available No Clinical Annotations available VA
rs1799998 -344T>C, 143999600A>G, 4660T>C, 57273149A>G, CYP11B2 ¿344T/C
A > G
5' Flanking
No VIP available CA VA
rs1800545 -217G>A, 112837538G>A, 5749G>A, 63642002G>A
G > A
5' UTR
No VIP available No Clinical Annotations available VA
rs1800888 148206885C>T, 491C>T, 491T>C, 5730C>T, 9369812C>T, ADRB2: 164Thr>Ile, Ile164, Thr164Ile
C > T
Missense
Thr164Ile
No VIP available No Clinical Annotations available VA
rs1801058 1361T>C, 1457T>C, 1560504T>C, 3039150T>C, 78808T>C, Val454Ala, Val486Ala
T > C
Missense
Val486Ala
No VIP available CA VA
rs1801252 115804036A>G, 145A>G, 5231A>G, 66608500A>G, ADRB1:49Ser>Gly, ADRB1:Ser49Gly, Ser49Gly
A > G
Missense
Ser49Gly
rs1801253 115805056G>C, 1165C>G, 1165G>C, 6251G>C, 66609520G>C, ADRB1:389Arg>Gly, ADRB1:Arg389Gly, Gly389Arg
G > C
Missense
Gly389Arg
No VIP available No Clinical Annotations available VA
rs2106809 13499823A>G, 15618061A>G, 186+788T>C, 7132T>C
A > G
Intronic
No VIP available CA VA
rs2144297 127-50120T>C, 230263844T>C, 23781623T>C, 65889T>C
T > C
Intronic
No VIP available CA VA
rs2144300 127-19048C>T, 230294916C>T, 23812695C>T, 96961C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2230345 121086097A>T, 122A>T, 71890561A>T, Gln41Leu
A > T
Missense
Gln41Leu
No VIP available CA VA
rs2301339 10250G>A, 47044G>A, 6894624G>A, 6954624G>A, 700-126G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs292449 -241-17578G>C, -242+6092G>C, -300G>C, 123-17578G>C, 188472G>C, 3685945G>C, 55895081G>C, 99-17578G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs2932538 -775A>G, -890A>G, 113216543A>G, 83188461A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2960306 1511853G>T, 194G>T, 2990499G>T, 30157G>T, 98G>T, Arg33Leu, Arg65Leu
G > T
Missense
Arg65Leu
No VIP available CA VA
rs3213619 -129T>C, 117372T>C, 25263036A>G, 87230193A>G, ABCB1:T-129C
A > G
5' UTR
No VIP available No Clinical Annotations available VA
rs340874 214159256T>C, 7677035T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs4149601 -315-16229G>A, -326G>A, -404G>A, 110182G>A, 24G>A, 3607655G>A, 49-16229G>A, 55816791G>A, Gln8=
G > A
5' UTR
Gln8Gln
No VIP available No Clinical Annotations available VA
rs4253778 1160-396G>C, 26021203G>C, 46630634G>C, 89136G>C, PPARA: IVS7 2498 G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs4331 14619A>G, 2193A>G, 26838204A>G, 471A>G, 61564052A>G, Ala157=, Ala731=
A > G
Synonymous
Ala157Ala
No VIP available CA VA
rs4648287 10610T>C, 1406-56T>C, 186643950A>G, 38132592A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4762 230845977G>A, 24363756G>A, 620C>T, 9360C>T, AGT:Thr174Met, Thr207Met, angiotensinogen T174M
G > A
Missense
Thr207Met
No VIP available No Clinical Annotations available VA
rs4961 1378G>T, 1428061G>T, 2906707G>T, 66124G>T, ADD1:Gly460Trp, Gly460Trp, alpha-adducin Gly460Trp, rs4961 G>T
G > T
Missense
Gly460Trp
No VIP available No Clinical Annotations available VA
rs4994 190T>C, 25681944A>G, 37823798A>G, 5387T>C, ADRB3 T727C, ADRB3:Trp64Arg, Trp64Arg
A > G
Missense
Trp64Arg
No VIP available No Clinical Annotations available VA
rs5050 -58A>C, 230849886T>G, 24367665T>G, 5451A>C
T > G
5' UTR
No VIP available CA VA
rs5051 -44G>A, 230849872C>T, 24367651C>T, 5465G>A, AGT G(-6)A
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs5186 *86A>C, 148459988A>C, 49331A>C, 54955134A>C, AGTR1:1166A/C, AGTR1:1166A>C, AGTR1:116A>C, AGTR1:A1166C, AT, R A1166C, angiotensin II type 1 receptor A1166C
A > C
3' UTR
No VIP available CA VA
rs5370 10727G>T, 12236255G>T, 12296255G>T, 591G>T, 594G>T, Lys197Asn, Lys198Asn
G > T
Missense
Lys198Asn
No VIP available CA VA
rs5443 10501C>T, 47295C>T, 6894875C>T, 6954875C>T, 825C>T, GNB3:825C>T, GNB3:Ser275Ser, Ser275=
C > T
Synonymous
Ser275Ser
No VIP available CA VA
rs688 11227602C>T, 1269C>T, 1392C>T, 1410C>T, 1650C>T, 1773C>T, 2490404C>T, 32546C>T, Asn423=, Asn464=, Asn470=, Asn550=, Asn591=, LDLR: 16730C>T
C > T
Synonymous
Asn464Asn
No VIP available CA VA
rs699 230845794A>G, 24363573A>G, 803T>C, 9543T>C, AGT M235T, AGT Met235Thr, AGT:Met235Thr, angiotensinogen M235T
A > G
Missense
Met268Thr
No VIP available No Clinical Annotations available VA
rs75982813 -885A>G, 3501872A>G, 4399A>G, 55711008A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs871606 2139128T>C, 54799245T>C
T > C
Not Available
No VIP available CA VA
rs9940629 1364+36790A>G, 271937A>G, 54004811A>G, 7619010A>G
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142
2D structure from PubChem
provided by PubChem

Overview

Generic Names
Trade Names
  • Aircrit
  • Alinor
  • Altol
  • Anselol
  • Antipressan
  • Apo-Atenolol
  • Atcardil
  • Atecard
  • Atehexal
  • Atenblock
  • Atendol
  • Atenet
  • Ateni
  • Atenil
  • Atenol
  • Atenol 1A Pharma
  • Atenol AL
  • Atenol Acis
  • Atenol Atid
  • Atenol CT
  • Atenol Cophar
  • Atenol Fecofar
  • Atenol GNR
  • Atenol Gador
  • Atenol Genericon
  • Atenol Heumann
  • Atenol MSD
  • Atenol NM Pharma
  • Atenol Nordic
  • Atenol PB
  • Atenol Quesada
  • Atenol Stada
  • Atenol Tika
  • Atenol Trom
  • Atenol Von CT
  • Atenol-Mepha
  • Atenol-Ratiopharm
  • Atenol-Wolff
  • Atenolin
  • Atenomel
  • Atereal
  • Aterol
  • Betablok
  • Betacard
  • Betasyn
  • Betatop GE
  • Blocotenol
  • Blokium
  • Cardaxen
  • Cardiopress
  • Corotenol
  • Cuxanorm
  • Duraatenolol
  • Duratenol
  • Evitocor
  • Farnormin
  • Felo-Bits
  • Hipres
  • Hypoten
  • Ibinolo
  • Internolol
  • Jenatenol
  • Juvental
  • Lo-Ten
  • Loten
  • Lotenal
  • Myocord
  • Normalol
  • Normiten
  • Noten
  • Oraday
  • Ormidol
  • Panapres
  • Plenacor
  • Premorine
  • Prenolol
  • Prenormine
  • Prinorm
  • Scheinpharm Atenol
  • Seles Beta
  • Selobloc
  • Serten
  • Servitenol
  • Stermin
  • Tenidon
  • Teno-Basan
  • Tenobloc
  • Tenoblock
  • Tenolol
  • Tenoprin
  • Tenormin
  • Tenormine
  • Tensimin
  • Tredol
  • Unibloc
  • Uniloc
  • Vascoten
  • Vericordin
  • Wesipin
  • Xaten
Brand Mixture Names
  • Tenoretic (atenolol + chlorthalidone)

PharmGKB Accession Id:
PA448499

Description

A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect.

Source: Drug Bank

Indication

For the management of hypertention and long-term management of patients with angina pectoris

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.

Source: Drug Bank

Pharmacology

Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the management of hypertension and edema.

Source: Drug Bank

Food Interaction

Consult your doctor before taking large amounts of Vitamin K (Green leafy vegetables).|Take 30-60 minutes before meals, take at the same time each day.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic (minimal)

Source: Drug Bank

Protein Binding

Plasma protein binding is 6-16%

Source: Drug Bank

Absorption

Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces.

Source: Drug Bank

Half-Life

6-7 hours

Source: Drug Bank

Toxicity

LD 50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.

Source: Drug Bank

Route of Elimination

Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces. Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.

Source: Drug Bank

Chemical Properties

Chemical Formula

C14H22N2O3

Source: Drug Bank

Isomeric SMILES

CC(C)NCC(COc1ccc(cc1)CC(=O)N)O

Source: OpenEye

Canonical SMILES

CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1

Source: Drug Bank

Average Molecular Weight

266.3361

Source: Drug Bank

Monoisotopic Molecular Weight

266.16304258

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Beta-agonist/Beta-blocker Pathway, Pharmacodynamics
    Simplified pharmacodynamic pathway of drug action on beta 2 adrenergic receptor in a stylized airway cell.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRB1 (source: Drug Bank)

Drug Interactions

Drug Description
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol Ampicillin decreases bioavailability of atenolol (source: Drug Bank)
atenolol Ampicillin decreases bioavailability of atenolol (source: Drug Bank)
acetohexamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
acetohexamide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
ampicillin Ampicillin decreases bioavailability of atenolol (source: Drug Bank)
ampicillin Ampicillin decreases bioavailability of atenolol (source: Drug Bank)
chlorpropamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
chlorpropamide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
clonidine Increased hypertension when clonidine stopped (source: Drug Bank)
clonidine Increased hypertension when clonidine stopped (source: Drug Bank)
dihydroergotamine Ischemia with risk of gangrene (source: Drug Bank)
dihydroergotamine Ischemia with risk of gangrene (source: Drug Bank)
dihydroergotoxine Ischemia with risk of gangrene (source: Drug Bank)
dihydroergotoxine Ischemia with risk of gangrene (source: Drug Bank)
diltiazem Increased risk of bradycardia (source: Drug Bank)
diltiazem Increased risk of bradycardia (source: Drug Bank)
disopyramide The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
disopyramide The beta-blocker, atenolol, may increase toxicity of disopyramide. (source: Drug Bank)
epinephrine Hypertension, then bradycardia (source: Drug Bank)
epinephrine Hypertension, then bradycardia (source: Drug Bank)
ergonovine Ischmeia with risk of gangrene (source: Drug Bank)
ergonovine Ischmeia with risk of gangrene (source: Drug Bank)
ergotamine Ischemia with risk of gangrene (source: Drug Bank)
ergotamine Ischemia with risk of gangrene (source: Drug Bank)
fenoterol Antagonism (source: Drug Bank)
fenoterol Antagonism (source: Drug Bank)
formoterol Antagonism (source: Drug Bank)
formoterol Antagonism (source: Drug Bank)
glibenclamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glibenclamide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
gliclazide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
gliclazide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
glipizide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glipizide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
glisoxepide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glisoxepide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
glycodiazine The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glycodiazine The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
ibuprofen Risk of inhibition of renal prostaglandins (source: Drug Bank)
ibuprofen Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
insulin-glargine The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
isoproterenol Antagonism (source: Drug Bank)
isoproterenol Antagonism (source: Drug Bank)
lidocaine The beta-blocker increases the effect and toxicity of lidocaine (source: Drug Bank)
lidocaine The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine. (source: Drug Bank)
methysergide Ischemia with risk of gangrene (source: Drug Bank)
methysergide Ischemia with risk of gangrene (source: Drug Bank)
orciprenaline Antagonism (source: Drug Bank)
orciprenaline Antagonism (source: Drug Bank)
pirbuterol Antagonism (source: Drug Bank)
pirbuterol Antagonism (source: Drug Bank)
piroxicam Risk of inhibition of renal prostaglandins (source: Drug Bank)
piroxicam Risk of inhibition of renal prostaglandins (source: Drug Bank)
prazosin Risk of hypotension at the beginning of therapy (source: Drug Bank)
prazosin Risk of hypotension at the beginning of therapy (source: Drug Bank)
procaterol Antagonism (source: Drug Bank)
procaterol Antagonism (source: Drug Bank)
repaglinide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
repaglinide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
salbutamol Antagonism (source: Drug Bank)
salbutamol Antagonism (source: Drug Bank)
salmeterol Antagonism (source: Drug Bank)
salmeterol Antagonism (source: Drug Bank)
terbutaline Antagonism (source: Drug Bank)
terbutaline Antagonism (source: Drug Bank)
tolazamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
tolazamide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
tolbutamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
tolbutamide The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
verapamil Increased effect of both drugs (source: Drug Bank)
verapamil Increased effect of both drugs (source: Drug Bank)
atenolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol Increased hypertension when clonidine stopped (source: Drug Bank)
atenolol Increased hypertension when clonidine stopped (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Increased risk of bradycardia (source: Drug Bank)
atenolol Increased risk of bradycardia (source: Drug Bank)
atenolol The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
atenolol The beta-blocker, atenolol, may increase the toxicity of disopyramide. (source: Drug Bank)
atenolol Hypertension, then bradycardia (source: Drug Bank)
atenolol Hypertension, then bradycardia (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Ischemia with risk of gangrene (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
atenolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
atenolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
atenolol The beta-blocker, atenolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
atenolol Increased risk of hypotension. Initiate concomitant therapy cautiously. (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Antagonism (source: Drug Bank)
atenolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to atenolol: 55

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydrochlorothiazide-induced hyperuricaemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Journal of internal medicine. 2014. Vandell Alexander G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PROX1 Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment. Pharmacotherapy. 2013. Gong Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes. Hypertension. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of hypertension. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. PloS one. 2013. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and alpha,beta-ADR Blocker Response in EH Patients in China. PloS one. 2013. He Fazhong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives - Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Circulation. Cardiovascular genetics. 2012. Gong Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
G protein receptor kinase 4 polymorphisms: beta-Blocker Pharmacogenetics and treatment-related outcomes in Hypertension. Hypertension. 2012. Vandell Alexander G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Common beta1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular/Vascular Coupling: A Comparison With Atenolol (CENTRAL Study). Journal of clinical hypertension (Greenwich, Conn.). 2011. Shah Niren K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of translational medicine. 2012. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PloS one. 2012. O'Connor Christopher M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. American journal of hypertension. 2011. Smith Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenetics and genomics. 2011. Price Elvin Tyrone, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions. Clinical pharmacology and therapeutics. 2011. Johnson J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circulation. Cardiovascular genetics. 2010. Niu Yuxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and genomics. 2010. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein beta-3 subunit variant. Pharmacogenomics. 2010. Dörr Marcus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combination antihypertensive treatment: is initiation order important?. Journal of clinical hypertension (Greenwich, Conn.). 2010. Gums John G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenetics and genomics. 2010. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. British journal of clinical pharmacology. 2010. Mannheimer Buster, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics. 2010. Filigheddu Fabiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010. Cooper-DeHoff Rhonda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. Journal of clinical hypertension (Greenwich, Conn.). 2010. Beitelshees Amber L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clinical pharmacology and therapeutics. 2009. Johnson J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009. Kurnik Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circulation. Cardiovascular genetics. 2009. Beitelshees Amber L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clinical pharmacology and therapeutics. 2009. Bijl M J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clinical pharmacology and therapeutics. 2008. Pacanowski M A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and genomics. 2008. Kurnik Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). American heart journal. 2008. Gerhard Tobias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nature medicine. 2008. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and genomics. 2007. Chen Lu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clinical pharmacology and therapeutics. 2007. Fan X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clinical pharmacology and therapeutics. 2006. Iaccarino Guido, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2006. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and genomics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clinical pharmacology and therapeutics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and genomics. 2005. de Groote Pascal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. Journal of hypertension. 2004. Liljedahl Ulrika, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. The pharmacogenomics journal. 2005. Iaccarino G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment. BMC cardiovascular disorders. 2004. Liljedahl Ulrika, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clinical cardiology. 2004. Hallberg P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. American journal of hypertension. 2004. Kurland Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clinical pharmacology and therapeutics. 2003. Liu Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature medicine. 2003. Mialet Perez Jeanne, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology. 2003. White Hazel L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical pharmacology and therapeutics. 2003. Johnson Julie A, et al. PubMed
A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clinical pharmacology and therapeutics. 2003. Sofowora G G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. Journal of hypertension. 2001. Kurland L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clinical science (London, England : 1979). 2000. O'Shaughnessy K M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. Journal of hypertension. 1996. Dudley C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet. 1996. van Essen G G, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
65862-168-01
DrugBank:
DB00335
ChEBI:
2904
KEGG Drug:
D00235
PubChem Compound:
2249
PubChem Substance:
176216
46506915
IUPHAR Ligand:
548
Drugs Product Database (DPD):
828793
BindingDB:
25753
ChemSpider:
2162
Therapeutic Targets Database:
DAP000482
FDA Drug Label at DailyMed:
1b8a4689-3916-4f4b-b54a-bbb4e322d79b

Clinical Trials

These are trials that mention atenolol and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.